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Abstract
Background: Improved ability to rapidly rule-out Acute Myocardial Infarction (AMI) in patients presenting with
chest pain will promote decongestion of the Emergency Department (ED) and reduce unnecessary hospital
admissions. We assessed a new commercial Heart Fatty Acid Binding Protein (H-FABP) assay for additional
diagnostic value when combined with cardiac troponin (using a high sensitivity assay).
Methods: H-FABP and high-sensitivity troponins I (hs-cTnI) and T (hs-cTnT) were measured in samples taken
on-presentation from patients, attending the ED, with symptoms triggering investigation for possible acute coronary
syndrome. The optimal combination of H-FABP with each hs-cTn was defined as that which maximized the proportion
of patients with a negative test (low-risk) whilst maintaining at least 99 % sensitivity for AMI. A negative test comprised
both H-FABP and hs-cTn below the chosen threshold in the absence of ischemic changes on the ECG.
Results: One thousand seventy-nine patients were recruited including 248 with AMI. H-FABP < 4.3 ng/mL plus hs-cTnI
< 10.0 ng/L together with a negative ECG maintained >99 % sensitivity for AMI whilst classifying 40.9 % of patients as
low-risk. The combination of H-FABP < 3.9 ng/mL and hs-cTnT < 7.6 ng/L with a negative ECG maintained the same
sensitivity whilst classifying 32.1 % of patients as low risk.
Conclusions: In patients requiring rule-out of AMI, the addition of H-FABP to hs-cTn at presentation (in the absence of
new ischaemic ECG findings) may accelerate clinical diagnostic decision making by identifying up to 40 % of such
patients as low-risk for AMI on the basis of blood tests performed on presentation. If implemented this has the
potential to significantly accelerate triaging of patients for early discharge from the ED.
Keywords: Heart Fatty Acid Binding Protein, Rule-out strategy, Acute myocardial infarction, High-sensitivity troponin,
Accelerated diagnostic pathway, Multi-marker strategy
Background
Assessment of patients presenting to the Emergency
Department (ED) with symptoms suggestive of acute
coronary syndrome (ACS) represents a major clinical
challenge [1], since the majority of patients do not have
a final diagnosis of acute myocardial infarction (AMI)
[2–4]. Several established accelerated diagnostic path-
ways (ADPs) utilizing risk scores together with sampling
for cardiac troponin tests at presentation and at 2-or 3 h
have been shown to accurately identify up to 40 % of
patients as at low-risk of major adverse cardiac events
(MACE) [5, 6]. However, earlier identification of low-
risk patients at presentation alone could facilitate even
earlier discharge, and thus promote further reductions in
ED overcrowding and adverse patient outcomes [7–9].
A multi-marker strategy, combining hs-cTn with an
early cardiac marker may improve sensitivity and in-
crease the proportion of low-risk patients suitable for
early discharge by allowing a higher troponin threshold
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to be utilized. Heart Fatty Acid Binding Protein (H-FABP),
a highly myocardium-specific protein [10] and early rise
marker of ACS [11], is a potential candidate. Rising H-
FABP is detectable within at least 30 min following the
onset of AMI, with concentrations that peak at approxi-
mately 6–8 h [12, 13] compared to 10–13 h for hs-cTnI
and hs-cTnT [14]. In addition, the recent availability of a
commercial immunoturbidimetric assay for H-FABP
overcomes issues with previous point of care tests and
ELISA-based assays, and means this biomarker can now
be measured more reliably using the main laboratory
platform [15, 16], concurrently with hs-cTn assays, and
generate results within 20 min from blood sampling.
We assessed whether plasma H-FABP (by the new
assay) at presentation, in patients attending the ED with
chest pain, provides incremental value, in ruling out AMI,
when used in combination with concurrently measured
hs-cTnI (or hs-cTnT) and electrocardiography (ECG). In
this feasibility study we aimed to identify the combination
of H-FABP and hs-cTn that maximized the proportion of
low risk patients correctly identified, whilst maintaining a
high sensitivity for AMI. We have used the sensitivity
threshold of >99 % to determine the biomarker thresholds,
thereby ensuring a minimal false negative rate. Time
frame as subgroups was also assessed as we hypothesized
that H-FABP may add more diagnostic value in early pre-
senters, given its early rise in AMI (compared to hs-cTn).
It is recognised that <3 h following symptom onset that a
low value of hs-cTn alone is insufficient to rule-out AMI
(ESC 2015 guidelines).
Methods
Participants
We conducted a feasibility study on patients from the
Christchurch hospital arm of the ADAPT study
(ACTRN12611001069943) [3]. The protocol was ap-
proved by the Southern Health and Disability Ethics Com-
mittee, New Zealand (Ethics reference no: URA/07/06/
048/ AM02), and all patients provided written informed
consent. In brief, consecutive patients presenting acutely
to the emergency department (ED) with symptoms sug-
gestive of AMI, as per American Heart Association case
definitions, were enrolled [17]. Exclusion criteria were any
of the following: age <18 years; unable or unwilling to
provide informed consent; a clear cause other than ACS
for the symptoms; ST Segment Elevation Myocardial
Infarction (STEMI); staff considered recruitment to be
inappropriate (eg. receiving palliative treatment); transfer
from another hospital; pregnancy; or inability to be con-
tacted after discharge Patient assessment included blood
sampling for contemporary TnI (c-TnI) at presentation
and 6 to 12 h later in accordance with contemporaneous
international guidelines [17, 18].
Outcomes
The primary end point was AMI during initial hospital
attendance. AMI diagnosis was based on evidence of
myocardial necrosis, together with clinical features con-
sistent with myocardial ischaemia (ischaemic symptoms,
ECG changes or imaging evidence) [19]. Necrosis was
diagnosed on the basis of a rising or falling pattern of the
routine laboratory c-TnI (ARCHITECT c-TnI assay,
Abbott), with at least one value above the 99th percentile
(0.028 ng/mL) [20, 21]. Adjudication of the presence of
AMI was performed independently by two cardiologists,
and a third cardiologist made an independent final adjudi-
cation in cases of disagreement. Cardiologists were
blinded to hs-cTnI, hs-cTnT and H-FABP results but had
access to clinical records, ECGs, and serial non-high sensi-
tivity c-TnI (ARCHITECT c-TnI assay, Abbott) results
from routine care. Ischaemic ECG changes were defined
using previous criteria [22–24].
Assays
In addition to routine clinical tests, study samples
were collected at presentation. EDTA and lithium
heparin plasma were separated and frozen at −80 °C,
within 2 h of sampling for later analysis using hs-
cTnI and hs-cTnT, and updated H-FABP assays, re-
spectively. Hs-cTnI concentrations were measured on
the ARCHITECT STAT platform (Abbott Laborator-
ies, Abbott Park, Illinois). The assay has a limit of
detection (LoD) of 2 ng/L, 99th percentile among
healthy subjects of 26 ng/L, and sex-specific 99th
percentiles of 34 ng/L for men and 16 ng/L for
women. Hs-cTnT concentrations were measured with
the Roche Elecsys hs-cTnT assay (Roche Diagnostics
Limited, Switzerland). The hs-cTnT assay has a LoD
of 5 ng/L and a 99th percentile of the upper refer-
ence limit of 14 ng/L. H-FABP concentrations were
measured with an immunoturbidimetric H-FABP
assay (Randox Laboratories Limited, United King-
dom) on the ARCHITECT platform. The H-FABP
assay can be performed concurrently with hs-cTnI
and hs-cTnT assays on the same sample, and re-
quires 20 min from the time of blood sampling to
obtain a value. The 99th percentile of H-FABP assay
in a healthy reference population is 3.6 ng/mL and
LoD of 0.75 ng/mL [16]. No sex-specific differences
in the 99th percentile concentrations of H-FABP
have been shown [16].
Optimum assay threshold determination
The primary goal was to determine the optimal combin-
ation of H-FABP with each hs-cTn assay which yielded
the maximum proportion of low-risk patients whilst
maintaining a minimum sensitivity for AMI of 99 %. We
defined low-risk (of AMI), as those patients with a
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negative test, providing that the strategy has a sensitivity
>99 %. The choice of 99 % sensitivity for AMI to deter-
mine the optimal marker thresholds was based on a
survey suggesting this sensitivity, in ruling out major
adverse cardiac events (MACE), is acceptable to most
ED clinicians [25]. For each combination of H-FABP
from LoD to 10 ng/mL (in steps of 0.1 ng/mL) and
high-sensitivity troponin (hs-cTnI from the LoD to
34 ng/L in steps of 0.1 ng/L; hs-cTnT from the LoD to
14 ng/L in steps of 0.1 ng/L) the proportion low risk and
sensitivity for AMI was determined in combination with
the ECG (Fig. 1). This enabled a contour plot of sensitiv-
ities at sensitivities of 90 to 100 % in steps of 1 % to be
drawn on the H-FABP - hs-cTn plane.
We also determined the proportion of patients with a
negative test and sensitivity for AMI where a positive
test was defined as ECG positive or (i) H-FABP ≥99th
percentile, (ii) hs-cTn ≥ LoD, (iii) hs-cTn ≥99th percent-
ile, (iv) hs-cTn or H-FABP ≥99th percentile, (v) hs-cTn
≥99th percentile or H-FABP ≥ the optimal Receiver
Operator Characteristic curve (ROC) derived threshold
(the threshold which maximized the combination of
sensitivity and specificity in the group of patients in
which the hs-cTn was <99th percentile), (vi) hs-cTnT ≥
the threshold which had >99 % sensitivity for AMI.
Furthermore, ECG alone and together with H-FABP
was also tested in combination with hs-cTnI only using
sex-specific ≥99th percentile thresholds of 34 ng/L for
men and 16 ng/L for women as a positive test. The po-
tential of time from symptom onset to ED admission
blood sampling to influence results was assessed by ana-
lysis of subgroups of >3 h, 3 to 6 h and >6 h from symp-
tom onset to blood sampling. The estimated number of
bed days saved per patient was calculated as a propor-
tion of the total number of bed days for those patients
with a negative test for the optimized thresholds for
AMI-rule out, compared to the total number of bed
days for all patients.
Statistical analyses
Categorical data were expressed as numbers (percent-
ages), and continuous data were expressed as mean (SD)
or median (inter-quartile range (IQR)). The proportions
of each of the AMI rule-out strategies-positive and –
negative groups were reported along with the sensitivity
and negative predictive values for AMI for each test.
Confidence intervals are exact binominal 95 % confi-
dence intervals. Subgroup group analysis was under-
taken using the Chi-square test. Analyses were
performed using SPSS version 22.0 (SPSS, Inc., Chicago,
Illinois), or R [26] to determine the optimal thresholds.
Results
Patients were enrolled consecutively between November
2007 and February 2011 at the Christchurch Hospital
Emergency Department in Christchurch, New Zealand.
1184 patients were recruited. H-FABP, hs-cTnI and
hsTnT results were available in 1079 patients (Fig. 2).
Patients were predominantly male (59 %), aged 65 ±
13 years and presented a median (IQR) 6.2 (3.3–12.8)
hours after symptom onset, and were a high cardio-
vascular risk population (Table 1). 1005 (93 %) patients
were admitted to hospital for further investigation. An
adjudicated diagnosis of AMI was made in 248 (23.0 %)
patients.
Fig. 1 Methodology for calculating the each combination of H-FABP
from LoD to 10 ng/mL (in steps of 0.1 ng/mL) and high-sensitivity
troponin (hs-cTnI from the LoD to 34 ng/L in steps of 0.1 ng/L; hs-cTnT
from the LoD to 14 ng/L in steps of 0.1 ng/L) the proportion low risk
and sensitivity for AMI was determined in combination with the ECG
Assessed for Eligibility
(n=1435)
Exclusions (n=251)1
Did not meet inclusion criteria (n=29)
Declined or could not consent (n=86)
Previously recruited (n=136)
Transfer from other hospital       
Enrolled in another study (n=1)
Unable to obtain blood      (n=1)   Enrolled in ADAPT trial 
(n=1184)
Lost to Follow-up
(n=0)
Excluded from Analysis (n=105)2
Insufficient stored blood sample to measure 
H-FABP and/or hs-cTn  (n=105) 
Analysed patients
(n=1079) 
(n=1)  
Fig. 2 Consort diagram of study patients
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Single biomarkers in combination with ECG
H-FABP concentrations were greater in AMI than non-
AMI patients, as were hs-cTnI and hs-cTnT levels
(Fig. 3; P < 0.001). The median (IQR) H-FABP concen-
tration in AMI patients was 8.7 ng/mL (4.5–24.5) and
without AMI 3.4 ng/mL (2.2–5.3). H-FABP ≥99th
percentile threshold (3.6 ng/mL) in combination with
ECG had a sensitivity of only 90.3 % (95%CI 86.0 to
93.4) for AMI detection, with 24 false negatives. The
median (IQR) level of hs-cTnI in AMI was 174 ng/L
(126–222) and without AMI 4 ng/L (1–7), and for
hs-cTnT in AMI was 66 ng/L (36–96) and without
AMI 6 ng/L (3–9). Hs-cTnI performed similarly at
≥99th percentile threshold (26 ng/ml), Table 2. Hs-
cTnT at ≥99th percentile threshold (14 ng/mL) per-
formed slightly better, but still had a low sensitivity
of 94.8 %), Table 4.
The optimal threshold for hs-cTnI in combination
with ECG which had a sensitivity ≥99.0 % was 3.9 ng/L.
34.9 % of patients had a negative test. The optimal
threshold for hs-cTnT in combination with ECG which
had a sensitivity ≥99.0 % was 6.4 ng/L. 37.2 % of patients
had a negative test.
The sensitivity of hs-cTnI ≥ LoD with ECG was 100 %
(95 % CI 98.5 to 100.0), with 7.2 % of patients with a
negative test. The sensitivity of hs-cTnT ≥ LoD with
ECG was 99.6 % (95 % CI 97.8 to 99.9), with 30.0 % of
patients with a negative test.
H-FABP combined with hs-cTnI and ECG
The optimal combination that identified the maximum
proportion of negative test patients (40.9 %) whilst main-
taining >99 % sensitivity for AMI was H-FABP ≥4.3 ng/
mL with hs-cTnI ≥10.0 ng/L (Fig. 4; Table 2). H-FABP
and hs-cTnI at their respective 99th percentiles and
ECG classified 36.4 % of patients as negative for AMI,
with 4 false negatives (98.4 % sensitivity). The ROC
derived optimal threshold for H-FABP when combined
with hs-cTnI ≥99th percentile was 3.1 ng/mL. Applying
this threshold reduced the number of false negatives by
one (98.8 % sensitivity) and the overall proportion of
negative test patients to 29.9 %. Sensitivity and Negative
Predictive Value (NPV) were lower for the hs-cTnI sex-
specific 99th percentile thresholds in combination with
ECG when compared with the hs-cTnI 99th percentile
threshold (26 ng/L) and ECG, but similar when com-
bined with H-FABP (Table 3).
H-FABP combined with hs-cTnT and ECG
The optimal thresholds that identified the maximum
proportion of negative test patients whilst maintaining
>99 % sensitivity for AMI was H-FABP 3.9 ng/mL with
hs-cTnT threshold 7.6 ng/L, which (in combination with
ECG findings) classified 32.1 % of patients with a nega-
tive test (Fig. 5; Table 4). There were 7 false negatives
(97.2 % sensitivity) for the combination of H-FABP and
hs-cTnT at their respective 99th percentiles with ECG
and 34.2 % of patients were identified as negative for
AMI (Table 4). The ROC derived optimal threshold for
H-FABP combined with hs-cTnT ≥99th percentile was
Table 1 Characteristics of patient cohort at presentation and
outcomes (n = 1079)
Age, yrs (mean / SD) 65 ±13
Male, % 639 (59.2)
Systolic blood pressure, mmHg 145 ±27
Diastolic blood pressure, mmHg 80 ±14
Heart rate, bpm 74 ±19
Weight, kg 82.0 ±18.5
BMI, kg/m2 28.2 ±5.6
Ethnicity
Caucasian 993 (92.1)
NZ Maori 43 (4.0)
Pacific Island 10 (0.9)
Other 33 (3.1)
Risk factors at presentation
Hypertension 662 (61.4)
Diabetes 172 (15.9)
Dyslipidemia 622 (57.6)
Current smoking 157 (14.6)
Family history of coronary artery disease 664 (61.5)
Prior medical history
Angina 511 (47.4)
Acute myocardial infarction 324 (30.0)
Congestive heart failure 107 (9.9)
Cerebrovascular disease 135 (12.5)
Peripheral vascular disease 53 (4.9)
Coronary artery bypass graft 119 (11.0)
Percutaneous coronary intervention 265 (24.6)
Time of symptom onset to sample collection, h 6.2 (3.3–12.8)
Chest pain symptoms at presentation
Pain at rest 957 (88.7)
Pain in past 535 (49.6)
Pleuritic pain 167 (15.5)
Radiation of pain 704 (65.2)
Diaphoresis 521 (48.3)
Outcomes
ECG positive 181 (16.8)
STEMI 27 (2.5)
NSTEMI 221 (20.5)
Length of initial hospital attendance, h 50.1 (26.5–115.1)
Values are n (%) or mean ± sd, or median (lower quartile – upper quartile)
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3.0 ng/mL. Applying this threshold reduced the number
of false negatives by 2 (98.0 % sensitivity) and the overall
proportion of negative patients to 26.9 %.
Subgroup analysis
From 1016 patients with a documented date and time of
symptom onset, 215 (21 %) patients presented in <3 h,
273 (27 %) in 3–6 h, and 528 (52 %) after >6 h. Table 5
shows the sensitivity and proportion of negative test
patients identified by the optimal combination of H-FABP
and hs-cTn thresholds, according to duration from symp-
tom onset to sample collection.
Additional analysis
Using the optimal combination of H-FABP and hs-cTnI
or Hs-cTnT thresholds to rule-out index AMI, we esti-
mated that the total number of bed days per patient
could be reduced from 3.5 days to 2.7 days and 2.9 days
respectively, providing potential hospital bed savings of
up to 0.8 days (22 %) per presentation.
Discussion
In high-risk patients requiring AMI rule-out, the
addition of H-FABP to hs-cTnI at ED presentation, in
the absence of new ischaemic changes on ECG may ac-
celerate diagnostic decision making by identifying up to
40 % of such patients as low-risk for AMI on the basis
of blood tests performed at presentation. When ECG,
and H-FABP were combined with hs-cTnT, this multi-
marker strategy ruled out AMI in fewer patients (32 %).
Rather than simply reporting the sensitivity with a 95 %
confidence interval for a particular combination of H-
FABP and hs-cTn, we deliberately, and conservatively,
used a methodology to estimate the optimum combin-
ation of thresholds at high sensitivity (99 %) for AMI. This
is important, because at such high sensitivities even large
studies, such as this, will have large confidence intervals
(a) (b) (c)
Fig. 3 Scatter plots of a H-FABP, b hs-cTnI and c hs-cTnT concentrations at ED presentation in patients with and without an AMI diagnosis during
index admission (P > 0.001 for the difference between groups for each biomarker)
Table 2 Performance of H-FABP with hs-cTnI and ECG
Test AMI
(n = 255)
No AMI
(n = 845)
Total
(n = 1100)
Proportion
Negative Test (%)
Sensitivity (%) NPV (%)
Optimal combinationa : ECG positive or
hs-cTnI ≥10 ng/L or H-FABP ≥4.3 ng/mL
Positive 246 392 638 99.2 (97.1 to 99.8)
Negative 2 439 441 40.9 99.5 (98.4 to 99.9)
Hs-cTnI 99th percentile threshold:
ECG positive or hs-cTnI ≥26 ng/L
Positive 225 122 347 90.7 (86.5 to 93.7)
Negative 23 709 732 67.8 96.9 (95.3 to 97.9)
Hs-cTnI or H-FABP 99th percentile threshold:
ECG positive or hs-cTnI ≥26 ng/L
or H-FABP≥ 3.6 ng/mL
Positive 244 442 686 98.4 (95.9 to 99.4)
Negative 4 389 393 36.4 99.0 (97.4 to 99.6)
Hs-cTnI 99th percentile with H-FABP
ROC derivedb: ECG positive or
hs-cTnI≥ 26 ng/L or H-FABP≥ 3.1 ng/mL
Positive 245 511 756 98.8 (96.5 to 99.6)
Negative 3 320 323 29.9 99.1 (97.3 to 99.7)
Hs-cTnI threshold for >99.0 %
sensitivity: ECG or hs-cTnI≥ 3.9 ng/L
Positive 246 456 702 99.2 (97.1 to 99.8)
Negative 2 375 377 34.9 99.5 (98.1 to 99.9)
aStrategy that yielded the maximum proportion of low-risk patients whilst maintaining a minimum sensitivity for AMI of 99 %
bH-FABP ROC derived threshold which maximized the combination of sensitivity and specificity in patients negative for hs-cTnI and ECG
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which limit general application of the results. Our multi-
marker strategies utilizing the derivation of optimal
thresholds for H-FABP, hs-cTn and ECG ie. thresholds
that identified of the maximum proportion of negative pa-
tients whilst maintaining >99 % sensitivity, allowed the
greatest proportion of patients to be classified as low risk
(ie. negative test) with an acceptable sensitivity (ie. >99 %)
for AMI detection at presentation. The use of strategies
using pre-specified cut points, including the 99th percent-
ile thresholds for either hs-cTn and 99th percentile or
ROC-derived thresholds for H-FABP in combination with
a positive ECG, improved the sensitivity for AMI in com-
parison to the 99th percentile thresholds for hsTn and
ECG alone, but did not achieve >99 % sensitivity, consid-
ered an acceptable target by the majority of ED clinicians
[25]. Utilizing the hs-cTnI LoD threshold in combination
with a positive ECG resulted in no false negatives for
AMI, but less than 10 % of patients could be classified as
low-risk. In contrast, hs-cTnT at the LoD threshold in
combination with a positive ECG, classified 30 % of pa-
tients as low-risk for AMI, which was only slightly less
than utilizing the optimized rule-out strategy incorporat-
ing hs-cTnT, H-FABP and ECG (32.1 %). Subgroup ana-
lysis of our optimized biomarker strategies according to
time from onset of symptoms showed that the classifica-
tion of low-risk patients was not significantly greater in
early presenters versus later presenters.
A number of studies have evaluated the utility of “at
presentation” AMI rule-out strategies incorporating sen-
sitive or hs-cTn assays in patients with suspected cardiac
chest pain, but reported either unsatisfactory diagnostic
accuracies [27], or insufficient identification of low-risk
(negative test) patients suitable for early discharge [28, 29].
More recently, Shah and colleagues derived a threshold of
Fig. 4 A. Contour plot of the sensitivities (white lines) and heat map of the percentage of negative test for AMI for any combination of H-FABP
and hs-cTnI. Because multiple combinations of the two biomarkers can produce the same sensitivity we have plotted lines of constant sensitivity
(eg 99 %). The colours represent the proportion of patients who have a negative test for each possible combination of biomarkers. Red colours
represent few patients with negative tests, purple colours represent many patients with negative test. To focus on the high sensitivity areas we
have limited the biomarker values displayed to ≤9 ng/mL for H-FABP and <34 ng/L for hs-cTnI. A negative test is defined when H-FABP and
hs-cTnI concentrations are below the levels on the y and x axis respectively
Table 3 Performance of H-FABP with hs-cTnI and ECG using sex-specific 99th percentile hs-cTnI thresholds
AMI
(n = 255)
No AMI
(n = 845)
Total
(n = 1100)
Proportion
Negative Test
Sensitivity NPV
Hs-cTnI 99th percentile threshold: ECG positive
or hs-cTnI ≥16 ng/L (females) and ≥34 ng/L (males)
Positive 223 126 349 89.9 (85.5 to 93.1)
Negative 25 705 730 67.7 96.6 (95.0 to 97.7)
Hs-cTnI or H-FABP 99th percentile threshold:
ECG positive or hs-cTnI ≥16 ng/L (females)
or ≥34 ng/L (males) or H-FABP≥ 3.6 ng/mL
Positive 243 442 685 98.0 (95.4 to 99.1)
Negative 5 389 394 36.5 98.7 (97.1 to 99.5)
Hs-cTnI 99th percentile with H-FABP ROC deriveda:
ECG positive or hs-cTnI ≥16 ng/L (females)
or ≥34 ng/L (males) or H-FABP≥ 3.1 ng/mL
Positive 245 511 756 98.8 (96.5 to 99.6)
Negative 3 320 323 29.9 99.1 (97.3 to 99.7)
aH-FABP ROC derived threshold which maximized the combination of sensitivity and specificity in patients negative for hs-cTnI and ECG
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5 ng/L for hs-cTnI based on a target 99.5 % NPV in a co-
hort of patients without myocardial necrosis on presenta-
tion for the outcome of type 1 MI or cardiac death within
30 days [30]. We chose to use sensitivity for AMI rather
than NPV because it is not affected by disease prevalence.
Shah et al. observed a sensitivity of 98.9 % (95 % CI 97.9 to
99.4) for the primary outcome, and the proportion of pa-
tients with a negative test of 47.5 % in their derivation co-
hort [30]. Given the differences in AMI presentation rates
in New Zealand the well-developed primary care system
means many low risk patients do not present to EDs, it is
difficult to compare directly the proportion of negative
patients. Nevertheless, the proportion of negative test pa-
tients reported by Shah and colleagues is slightly greater
than we observed with our optimized multi-marker strat-
egy using hs-cTnI, but the sensitivity is slightly lower. A
study of 14,612 presentations, found that up to 61 % of pa-
tients with initially undetectable hs-cTnT levels (5 ng/L)
could be discharged directly from ED, with a NPV of
99.8 % (95%CI: 99.7 to 99.9) for AMI within 30 days, but
with a sensitivity of only 98.1 % (95%CI: 96.9 to 98.8) [31].
Several established accelerated diagnostic pathways
(ADPs) utilizing risk scores together with 0- and either
2- or 3 h cardiac troponin tests, have been shown to
Fig. 5 A Contour plot of the sensitivities (white lines) and heat map of the percentage of a negative test for AMI for any combination of H-FABP and
hs-cTnT. Because multiple combinations of the two biomarkers can produce the same sensitivity we have plotted lines of constant sensitivity (eg
99 %). The colours represent the proportion of patients who have a negative test for each possible combination of biomarkers. Red colours represent
few patients with negative tests, purple colours represent many patients with negative test. To focus on the high sensitivity areas we have limited the
biomarker values displayed to ≤9 ng/mL for H-FABP and <14 ng/L for hs-cTnT. A negative test is defined when H-FABP and hs-cTnT concentrations
are below the levels on the y and x axis respectively
Table 4 Performance of H-FABP with hs-cTnT and ECG
Test AMI
(n = 251)
No AMI
(n = 834)
Total
(n = 1085)
Proportion
Negative Test (%)
Sensitivity (%) NPV (%)
Optimal combinationa : ECG positive or
hs-cTnT ≥7.6 ng/L or H-FABP ≥3.9 ng/mL
Positive 246 487 733 99.2 (97.1 to 99.8)
Negative 2 344 346 32.1 99.4 (97.9 to 99.8)
Hs-cTnT 99th percentile threshold:
ECG positive or hs-cTnT ≥14 ng/L
Positive 235 253 488 94.8 (91.2 to 96.9)
Negative 13 578 591 54.8 97.8 (96.3 to 98.7)
Hs-cTnT or H-FABP 99th percentile threshold:
ECG positive or hs-cTnT ≥14 ng/L or
H-FABP≥ 3.6 ng/mL
Positive 241 469 710 97.2 (94.3 to 98.6)
Negative 7 362 369 34.2 98.1 (96.1 to 99.1)
Hs-cTnT 99th percentile with H-FABP ROC
derivedb: ECG positive or hs-cTnT≥ 14 ng/L or
H-FABP≥ 3.0 ng/mL
Positive 243 546 789 98.0 (95.4 to 99.1)
Negative 5 285 290 26.9 98.3 (96.0 to 99.3)
Hs-cTnT threshold for >99.0 % sensitivity:
ECG or hs-cTnT ≥ 6.4 ng/L
Positive 247 431 678 99.6 (97.8 to 99.9)
Negative 1 400 401 37.2 99.8 (98.6 to 100.0)
aStrategy that yielded the maximum proportion of low-risk patients whilst maintaining a minimum sensitivity for AMI of 99 %
bH-FABP ROC derived threshold which maximized the combination of sensitivity and specificity in patients negative for hs-cTnT and ECG
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accurately identify up to 40 % of patients as at low-risk for
MACE at 30 days in randomized controlled trials [5, 6].
We have previously reported that use of an ADP incorpor-
ating the Thrombolysis in Myocardial Infarction score, 0 h
ECG, and 0- and 2-h troponin tests, enabled safe early dis-
charge of almost double the proportion of patients com-
pared to the standard care pathway (19.3 % versus 11.0 %,
respectively), with a further 12.9 % of inpatients classified
as low-risk although none ultimately were diagnosed with
ACS [5]. Mahler and colleagues, showed that compared to
usual care, implementation of the HEART Pathway, an
ADP using the HEART [32] score with 0- and 3-h cardiac
troponin tests), resulted in a significant reduction in object-
ive cardiac testing and increase in early discharge without
any MACE at 30 days (39.7 % versus 18.4 %, P < 0.001) in
low-risk patients [6].
The strategy derived in this feasibility study, has the
potential to improve the utility of AMI rule-out in the
ED setting, as the test was negative in up to 40 % of pa-
tients on the basis of presentation blood sampling alone.
The ability to safely identify a similar number of low-
risk patients at presentation rather than after 2 h or
more, currently required for established ADPs, will have
likely benefits to both patients and the health care
resources, since it is well established that prolonged
assessment and ED overcrowding contribute to worse
patient outcomes [7–9]. Furthermore, implementation of
this strategy has a potential advantage over other ADPs
in that it does not rely on expert clinical evaluation and
comprehensive scoring systems that may be difficult to
implement in routine clinical practice with less experi-
enced clinicians or in overcrowded, busy ED depart-
ments. Nevertheless, the use of clinical scores in
combination with our marker based strategy should be
evaluated. Utilizing an “at presentation” AMI rule-out
strategy may also have health cost benefits, as implied in
the present study, with a reduction in bed days.
Limitations
Our marker based strategies deliberately did not take
into account clinical parameters, which should always be
integrated into clinical decision-making. Incorporation
of clinical assessment would potentially increase sensi-
tivity, but may decrease the proportion of patients classi-
fied as low-risk (negative test). The underlying data are
derived from a cohort with an AMI rate higher than
most in the international literature and with relatively
late presentation. This probably reflects effective pre-
screening by the local primary health care system, redu-
cing the proportion of very low-risk patients presenting
to the ED. The current findings require validation in
other ‘high risk’ and “lower cardiac risk” cohorts, and
further analyses are underway. Compared to many ED
populations, because of the well-funded primary health
care system in New Zealand the prevalence of AMI was
high. This means that translation of these optimal rule-
out strategies to the general population (comprising
more low-risk patients), would likely increase the NPV.
Whether clinicians can effectively implement the opti-
mized multi-marker strategies for on presentation rule-
out of AMI in clinical practice and whether these strat-
egies will improved discharge rates, is unknown. There
may be reluctance by clinicians to adopt alternative rule-
out strategies to those that utilize the hs-cTn 99th per-
centile threshold, despite this being a somewhat arbi-
trary and not sensitive cut-point to rule-out AMI [33].
Another issue is that below these thresholds the CV for
these hs-cTn assays is much greater than 10 %. This
would be even more of an issue for single hs-cTn strat-
egies with ultra-low concentrations used to rule-out
AMI. We note that when combining biomarkers to de-
rive optimal thresholds the sensitivity contours were not
perfectly smooth. This highlights the need for validation
of the derived thresholds in other cohorts. It is import-
ant to note, that while the potential for cost savings may
occur in patients classified as a negative test, with a re-
duction in hospital days, patients may still require cardi-
ology investigations as part of their outpatient follow-up.
We had limited power for the subgroup analyses, which
found no significant effect of the optimized H-FABP
multi-marker strategies, according to timing from symp-
tom onset to ED admission blood sampling (>3 h, 3 to
Table 5 Subgroup Analyses Performance of H-FABP with hs-cTn and ECG according to duration from symptom onset to sample
collection
Hours from onset of
symptoms to sample
collection
Proportion of patients with
documented date and time
of symptom onset, n (%)
Optimal combinationa : ECG positive or
hs-cTnI ≥10 ng/L or H-FABP ≥4.3 ng/mL
Optimal combinationa : ECG positive or
hs-cTnT ≥7.6 ng/L or H-FABP ≥3.9 ng/mL
Sensitivity (%) Proportion Negative
Test Patientsb
Sensitivity (%) Proportion Negative
Test Patientsc
<3 h 215 (21) 100.0 (96.0 to 100.0) 43.3 % 100.0 (96.0 to 100.0) 34.4 %
3–6 h 273 (27) 100.0 (93.7 to 100.0) 43.2 % 98.2 (90.7 to 99.7) 34.4 %
>6 h 528 (52) 98.7 (95.3 to 99.6) 38.4 % 99.3 (96.3–99.9) 30.3 %
aStrategy that yielded the maximum proportion of low-risk patients whilst maintaining a minimum sensitivity for AMI of 99 %
bP-value is 0.30 for comparison of proportion of negative test patients between subgroups (chi-square analysis)
cP-value is 0.37 for comparison of proportion of negative test patients between subgroups (chi-square analysis)
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6 h and >6 h). The proportion of patients classified with
a negative test was, however, reduced when sample col-
lection was greater than 6 h from onset of chest pain.
Conclusions
In this study, H-FABP in combination with hs-cTn, for
patients without ischemic ECG changes, improved the
rule-out of AMI at ED presentation, compared to hs-
cTn alone and ECG, while maintaining >99 % sensitivity
for AMI. This is a potential strategy for implementation
in clinical practice, and would allow up to 40 % of
patients to be classified as low risk and suitable for early
discharge and outpatient review. If implemented this
strategy would likely have important consequences to
patient flow within the ED and to hospital budgets, and
patient morbidity and mortality.
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